E VistaGen Therapeutics: Interesting Prospects


The current clinical trials in place will validate the efficacy of AV-101. The phase 2 monotherapy treatment for MDD using AV-101 is expected to complete by the end of 2017. That means that investors should anticipate data around the 1st half of 2018. That will be a major inflection point for the company, because it will show top-line data of AV-101 as a monotherapy. The adjunctive phase 2 data is expected to launch sometime in 2018. Data from this trial could be expected as early as 1st half 2019. The first set of data for the monotherapy study is not that far away, which makes it a major catalyst that could greatly affect the stock price.

Drug Versatility

A big advantage for any biotech company is when one drug can be applied to a multitude of indications. That is the case here with AV-101. VistaGen has stated that this drug can be applied to a multitude of Central Nervous System (CNS) indications. Such indications include: Neuropathic pain, epilepsy, Bipolar disorder, depression, and a few others. That means that the use of AV-101 does not stop with just MDD. There are many indications that Vistagen can choose to go after next. The likely indication would be the Neuropathic pain market. For starters, the neuropathic pain market is estimated to climb to $8.3 billion by 2024. I would say the most important aspect being that new treatment options are needed, because current pain medications are opioids. The problem is that there is a major opioid addiction epidemic, which leads to overdose in many patients. On top of that, 4 of 5 heroin addicts started off with opioids before they branched off to other drugs. With a successful efficacy profile proven by AV-101 for pain, things could change.

Acquisition Potential

Another massive potential for VistaGen is acquisition. There was a privately held company by the name of Naurex Inc, which was acquired by Allergan PLC for $560 million in cash. Naurex also targets MDD, targeting the pathways NMDAR/AMPA, but intravenously. Think about that for a second. Allergan ponied up money to buy this company that treats MDD using the same pathways as VistaGen, but through IV administration. If Naurex, which uses IV administration, was bought for that much, how much do you think big pharma would pay to buy a company like VistaGen with an oral form of therapy? After all, oral administration is the preferred route for treatments, mainly because it is easier access for patients instead of having to receive an IV at a medical center or hospital.

View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time, and ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Paul B 3 years ago Member's comment

When I say I was in a different place that was when the drug was intravenous but until Wednesday very good. Regards Paul

Ayelet Wolf 3 years ago Member's comment

Thanks for sharing but I'm not clear what your point is Paul.

Paul B 3 years ago Member's comment

I suffer from MDD and was admitted to a psychiatric hospital.There are two hospitals in the UK and they are testing ketamine. One is Oxford and the other One is Northampton.The Dr ask me if I would be willing to take part in the test and when you suffered with depression for many years you would do anything to get out of the big black cloud that makes life unbearable.it was amazing it was like you were in a different place,so relaxing.The trials were every Friday you would document everyday on your computer.For me it was very effective but I noted it would last until Wednesday obviously this is a trial and as time when by they would now what dose you would require.But unfortunately I was taken of the test because I was on a very strong opioid and obviously they were testing a new drug and could not take any chances as it did not have a license. Regards Paul

Derek Snyder 3 years ago Member's comment

Your argument for acquisition sounds convincing, but I wonder if there have been any such overtures. Know if that's the case? Which companies would be the most likely to target #Vistagen? $VTGN.

David M. Green 3 years ago Member's comment

Looks promising. Sounds like $VTGN should be getting more love from investors.

Bill Johnson 3 years ago Member's comment

Definitely sounds like some interesting prospects indeed! $VTGN

Alexis Renault 3 years ago Member's comment

Thanks Terry Chrisomalis, can you explain what a "first-line, second-line, and third-line of treatment" is?

Terry Chrisomalis 3 years ago Author's comment

That is taking one SSRI drug for 4-8 weeks then it not working, then taking another SSRI drug for 4-8 weeks and it not working etc. Then eventually following up with adding atypical antipsychotics

Alexis Renault 3 years ago Member's comment

Thanks Terry! Will take a closer look at $VTGN.